Clinical trial · Observational
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China
Multicenter Study for Risk Stratification of Patients Presenting With Symptoms Related to Lung Cancer Using the Lung Cancer Biomarker Panel (LCBP) in China
NCT01928836CI-TRIAL-00018044LCBPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to verify clinical utility of a simple blood test comprising of four protein- based markers for risk stratification of patients presenting symptoms related to lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Non-suspected lung cancer group
- description
- 1. Aged 40 to 75 years; 2. Male smoker (≥400 cig/year), female smoker or non-smoker; 3. Visible lung nodule lesion in the chest (based on local CT result); 4. Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery.
- label
- Suspected lung cancer group
- description
- 1. Aged 40 to 75 years; 2. Male smoker (≥400 cig/year), female smoker or non-smoker; 3. Visible lung cancer lesion in the chest (based on local CT result); 4. With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery.
Primary outcomes (1)
- measure
- Incidence rate of lung cancer
- timeFrame
- Up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Non-suspected lung cancer group (600 cases) 1. Aged 40 to 75 years; 2. Male smoker (≥400 cig/year), female smoker or non-smoker; 3. Visible lung nodule lesion in the chest (based on local CT result); 4. Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery. * Suspected lung cancer group (600 cases) 1. Aged 40 to 75 years; 2. Male smoker (≥400 cig/year), female smoker or non-smoker; 3. Visible lung cancer lesion in the chest (based on local CT result); 4. With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery. Exclusion Criteria: * Histopathological diagnosis result is unavailable, including patients only have cytology results of pleural effusion; * Already treated by chemotherapy or surgery
References
Publications (2)
- DERIVEDYang D, Zhang X, Powell CA, Ni J, Wang B, Zhang J, Zhang Y, Wang L, Xu Z, Zhang L, Wu G, Song Y, Tian W, Hu JA, Zhang Y, Hu J, Hong Q, Song Y, Zhou J, Bai C. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. Cancer. 2018 Jan 15;124(2):262-270. doi: 10.1002/cncr.31020. Epub 2017 Sep 20. PMID 28940455
- DERIVEDYang D, Zhou J, Zeng T, Yang Z, Wang X, Hu J, Song Y, Chen L, Peer D, Wang X, Bai C. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. Cancer Lett. 2015 Aug 28;365(1):57-67. doi: 10.1016/j.canlet.2015.05.001. Epub 2015 May 11. PMID 25976768